Intuitive Surgical’s just-released third-quarter 2026 results confirmed da Vinci procedure volume rose approximately 14% year over year, landing squarely in the 12.5–15% range and driving near-certain market-implied odds. Instruments and accessories revenue climbed 18% to $1.80 billion on the higher utilization, while 546 da Vinci systems were placed—315 of them the newer da Vinci 5 model—expanding the installed base 12% to 12,094. Worldwide procedures, including Ion, advanced 15%, supporting recurring revenue momentum and non-GAAP EPS of $3.00 that beat consensus. Full-year guidance of 14–15% da Vinci growth, expected near the midpoint, reinforces the quarter’s trajectory. The outcome could face revision only in the unlikely event of material restatement or reclassification of procedure counts by the company.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato1H6H1D7D30DALL
View resolved

Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti